Agoracom: Small Cap Investment - Zenith Epigenetics - Phase 1b/2 trial expected to initiate 1Q 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Phase 1b/2 trial expected to initiate 1Q 2019

posted on Mar 06, 2019 10:45AM

Tick tock guys. What's going on here? 25 days left in Q1 2019. Nothing up on ClinicalTrials.gov yet.

News released Nov 20, 2018: Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

"Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019"

1 Recommendations

RRSP to TFSA

Polar one

Mar 06, 2019 02:07PM

Re: RRSP to TFSA

narmac

Mar 06, 2019 02:20PM

Re: Phase 1b/2 trial expected to initiate 1Q 2019

narmac

Mar 06, 2019 03:04PM

Mar 06, 2019 04:59PM

Mar 06, 2019 07:05PM

Mar 07, 2019 07:38AM

Mar 07, 2019 09:36AM

Mar 07, 2019 11:17AM

Mar 07, 2019 01:27PM

Re: Phase 1b/2 trial expected to initiate 1Q 2019

Nextblockbuster

Mar 13, 2019 09:23AM

Reply New Message

Back To Forum List View

Please to post a reply